Appointment of Bruno Mäder as President and COO

Appointment of Bruno Mäder as President and COO

Boucherville, November 17, 2020

The JAMP Pharma Group is pleased to appoint Bruno Mäder as President and Chief Operating Officer (COO). Mr. Mäder initially joined the JAMP Pharma Group in 2019 as Managing Director of the Orimed Pharma subsidiary, which specializes in commercializing branded products in Canada. In his new role, he will report to the President and CEO, Louis Pilon. Mr. Mäder retains full responsibility for Orimed Pharma in addition to overseeing the JAMP Pharma Group operations as well as its biosimilar portfolio.

Bruno Mäder has proven his leadership in the pharmaceutical industry—a strength he has used to grow our Orimed subsidiary. I’m really excited that I can now count on him to support me in elevating the JAMP Pharma Group to become Canada’s largest pharmaceutical partner by providing diversified health solutions and enhancing the well-being of people and communities globally.

– Louis Pilon, President and CEO, JAMP Pharma Group

Bruno Mäder has worked in the pharmaceutical industry for almost 30 years. Before joining the JAMP Pharma Group, he was Vice-President of Market Access and Head of the Biosimilar and Diversified Brands Business Unit at Merck Canada. Prior to this role, he held several positions at Schering-Plough and at Merck when the two companies merged. While serving as Vice-President of the Immunology Division for Schering-Plough, he launched Remicade® in Canada, a product that, still today, ranks among the top on the Canadian market. In addition, Mr. Mäder served as Executive Chairman of Consumer Health Products (CHP) Canada from 2012 to 2014.

About the JAMP Pharma Group

The JAMP Pharma Group is a privately owned Québec company headquartered in the Montréal area. Having enjoyed remarkable growth over the past 10 years, the JAMP Pharma Group is present in all segments of the pharmaceutical market. The Group has a portfolio close to 270 generic molecules and leads the Canadian pharmaceutical industry in terms of new generic product launches based on Health Canada approvals from January to December 2019. It also ranks among the country’s top companies in terms of annual prescription volume according to IQVIA. The Group also has a Wampole–Laboratoire Suisse Division with more than 160 over-the-counter products including a wide range of vitamins, supplements and natural products, as well as prescription and branded products from its subsidiary Orimed Pharma.

L’article Appointment of Bruno Mäder as President and COO est apparu en premier sur JAMP Pharma.